Abstract
We conducted this study to evaluate the demography, clinical presentation, management and outcomes of medullary thyroid carcinoma (MTC) from the Indian context. This was a retrospective study of patients with MTC managed between January 2008 and December 2016. All pertinent data was collected and the results were analysed using STATA (v.13.1). MTC accounted for 90/2022 (4.45%) patients managed with thyroid cancer during the study period. The mean age of presentation was 40 years (range 14–70 years) with 47 males and 43 females. The most common presentation included goitre with cervical lymphadenopathy seen in 60 patients (66.7%). There were 11 patients (12.2%) with systemic metastasis at presentation. Rearranged during transfection (RET) testing was performed in 71 patients and was positive in 25 (35.2%). The mutations among these patients were seen in the following codons: 634 (12), 804 (8), 790 (3) and 618 (2). Persistent hypercalcitoninemia (calcitonin > 50 pg/ml) was observed in 62/80 (77.5%) patients. Forty patients underwent a meta-iodo-benzyl-guanidine (MIBG) scan in the postoperative period, 10 were positive. The mean duration of follow-up was 32 months and 10 patients defaulted from follow-up. Sixteen patients developed metastasis during the period of follow-up while eight patients expired. The mean survival was 85.75 months (95% CI 78.7–92.7). MTC accounted for 4.5% of thyroid carcinomas in this cohort among which 35% were hereditary. Persistent hypercalcitoninemia following surgery is seen in more than 70% of patients but this does not affect survival. RET screening should be performed for all patients with MTC as curative surgery can be offered for mutation positive offspring.
Similar content being viewed by others
References
Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc 25(6):567–610. https://doi.org/10.1089/thy.2014.0335
Allen SM, Bodenner D, Suen JY, Richter GT (2009) Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma. Laryngoscope 119(7):1303–1311. https://doi.org/10.1002/lary.20299
Rowland KJ, Moley JF (2015) Hereditary thyroid cancer syndromes and genetic testing. J Surg Oncol 111(1):51–60. https://doi.org/10.1002/jso.23769
Pai R, Nehru GA, Samuel P, Paul MJ, Thomas N, Premkumar JA, Hephzibah J, Shanthly N, Oommen R, Nair A, Seshadri MS, Rajaratnam S (2011) Mutational analysis of RET proto-oncogene among patients with medullary thyroid carcinoma and ‘at risk’ carriers from India. Clin Endocrinol 75(4):571–572. https://doi.org/10.1111/j.1365-2265.2011.04069.x
Nosé V (2011) Familial thyroid cancer: a review. Mod Pathol 24:S19–S33. https://doi.org/10.1038/modpathol.2010.147
Calvo J, Torrealba G, Sáenz A, Santamaría C, Morera E, Alvarado S, et al. Genetic and clinical features of medullary thyroid carcinoma: the experience of a single center in Costa Rica. J Cancer Epidemiol [Internet]. 2016 [cited 2017 Jan 5]; 2016. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149694/
Randolph GW, Maniar D (2000) Medullary carcinoma of the thyroid. Cancer Control 7(3):253–253. https://doi.org/10.1177/107327480000700305
Sakorafas GH, Friess H, Peros G (2008) The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr Relat Cancer 15(4):871–884. https://doi.org/10.1677/ERC-08-0098
Correia-Deur JEM, Toledo RA, Imazawa AT, Lourenco DM Jr, Ezabella MC et al (2009) Sporadic medullary thyroid carcinoma: clinical data from a university hospital. Clinics 64(5):379–386
Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H (2004) Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg 28(12):1271–1274. https://doi.org/10.1007/s00268-004-7608-9
Simões-Pereira J, Bugalho MJ, Limbert E, Leite V (2016) Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution. Oncol Lett 11(6):3870–3874. https://doi.org/10.3892/ol.2016.4482
Lee CR, Lee S, Son H, Ban E, Kang S-W, Lee J, Jeong JJ, Nam KH, Chung WY, Park CS (2016) Medullary thyroid carcinoma: a 30-year experience at one institution in Korea. Ann Surg Treat Res 91(6):278–287. https://doi.org/10.4174/astr.2016.91.6.278
Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q, Eisenberger CF, Röher HD, Knoefel WT (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246(5):815–821. https://doi.org/10.1097/SLA.0b013e31813e66b9
Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma. Ann Surg 229(6):880. https://doi.org/10.1097/00000658-199906000-00016
Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130(6):1044–1049. https://doi.org/10.1067/msy.2001.118380a
Moley JF (2010) Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Cancer Netw 8(5):549–556. https://doi.org/10.6004/jnccn.2010.0042
Bugalho MJM, Santos JR, Sobrinho L (2005) Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 91(1):56–60. https://doi.org/10.1002/jso.20269
de Crea C, Raffaelli M, Maccora D, Carrozza C, Canu G, Fadda G, Bellantone R, Lombardi CP (2014) Calcitonin measurement in fine-needle aspirate washouts vs. cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma. Acta Otorhinolaryngol Ital 34(6):399–405
Lorente-Poch L, Sancho JJ, Muñoz-Nova JL, Sánchez-Velázquez P, Sitges-Serra A (2015) Defining the syndromes of parathyroid failure after total thyroidectomy. Gland Surg 4(1):82–90. https://doi.org/10.3978/j.issn.2227-684X.2014.12.04
Brennan PA, Blythe JN, Herd MK, Habib A, Anand R (2012) The contemporary management of chyle leak following cervical thoracic duct damage. Br J Oral Maxillofac Surg 50(3):197–201. https://doi.org/10.1016/j.bjoms.2011.02.001
Dralle H, Gimm O, Simon D, Frank-Raue K, Görtz G, Niederle B et al (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22(7):744–751
Schreinemakers JMJ, Vriens MR, Valk GD, de Groot J-WB, Plukker JT, Bax KMA et al (2010) Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J Surg 34(4):852–860
Sousa A de A, Salles JMP, Soares JMA, Moraes GM de, Carvalho JR, Savassi-Rocha PR (2012) Predictors factors for post-thyroidectomy hypocalcaemia. Rev Col Bras Cir 39(6):476–482
Kluijfhout WP, van Beek D-J, Verrijn Stuart AA, Lodewijk L, Valk GD, van der Zee DC et al (2015) Postoperative complications after prophylactic thyroidectomy for very young patients with multiple endocrine neoplasia type 2. Medicine (Baltimore) 94(29):e1108
Machens A, Dralle H (2012) Simultaneous medullary and papillary thyroid cancer: a novel entity? Ann Surg Oncol 19(1):37–44
Biscolla RP, Ugolini C, Sculli M, Bottici V, Castagna MG, Romei C et al (2004) Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 14(11):946–952
Kim WG, Gong G, Kim EY, Kim TY, Hong SJ, Kim WB et al (2010) Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental. Clin Endocrinol (Oxf) 72(2):256–263
Finny P, Jacob JJ, Thomas N, Philip J, Rajarathnam S, Oommen R et al (2007) Medullary thyroid carcinoma: a 20-year experience from a centre in south India. ANZ J Surg 77(3):130–134
Van Veelen W, Groot D, B JW, Acton DS, Hofstra RMW, Höppener JWM et al (2009) Medullary thyroid carcinoma and biomarkers: past, present and future. J Intern Med 266(1):126–140
Fialkowski E, DeBenedetti M, Moley J (2008) Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32(5):754–765
Kebebew E, Kikuchi S, Duh QY, Clark OH (2000) Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135(8):895–901
Tisell LE, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99(1):60–66
Castellani MR, Seregni E, Maccauro M, Chiesa C, Aliberti G, Orunesu E et al (2008) MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging 52(4):430–440
Ilias I, Divgi C, Pacak K (2011) Current role of MIBG in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med 41(5):364–368
Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L (2000) Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25(2):273–282
Terezakis SA, Lee NY (2010) The role of radiation therapy in the treatment of medullary thyroid cancer. J Natl Compr Cancer Netw 8(5):532–540
Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD (2010) Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 102(2):175–178
Brierley JD (2011) Update on external beam radiation therapy in thyroid cancer. J Clin Endocrinol Metab 96(8):2289–2295
Sippel RS, Kunnimalaiyaan M, Chen H (2008) Current management of medullary thyroid cancer. The Oncologist 13(5):539–547
Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6):475–485
A T, F S, G P, M B (2011) Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics 12(8):618–625
Jiménez C, Hu MI-N, Gagel RF (2008) Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 37(2):481–496
Machens A, Dralle H (2008) Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf) 69(1):81–87
Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Uberta V, Boscaro M, Castagna MG, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R (2010) Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 163(6):963–963
Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R (2015) Twenty years of lesson learning: how does the genetic screening test impact the clinical management of medullary thyroid cancer? Clin Endocrinol 82(6):892–899
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
All authors declare that they have no conflict of interest.
Human Rights and Inform Consent
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
For this type of study formal consent is not required.
Rights and permissions
About this article
Cite this article
Cherian, A.J., Ramakant, P., Pai, R. et al. Outcome of Treatment for Medullary Thyroid Carcinoma—a Single Centre Experience. Indian J Surg Oncol 9, 52–58 (2018). https://doi.org/10.1007/s13193-017-0718-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-017-0718-2